RxDoctor Payments Data

Marisa Leonardo

Physician Assistant · Bronx, NYNPI 1104000231

Payments from drug & device makers

$8,161in general payments, 2019–2025

Across 364 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Scilex Pharmaceuticals Inc.$774
  • Amgen$762
  • Astellas Pharma US Inc$530
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$7,93497%
  • Education$2273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,161 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide91$178,773
FarxigaDapagliflozin Propanediol100$107,113
OzempicSemaglutide74$87,628
JardianceEmpagliflozin76$82,687
TrulicityDulaglutide45$54,827
Breztri AerosphereBudesonide/Glycopyr/Formoterol75$52,918
Xigduo XrDapaglifloz Propaned/Metformin67$52,768
JanuviaSitagliptin Phosphate48$50,625
JanumetSitagliptin Phos/Metformin Hcl25$32,315
MounjaroTirzepatide29$30,804
Tresiba Flextouch U-200Insulin Degludec26$29,329
GlyxambiEmpagliflozin/Linagliptin22$26,878
VascepaIcosapent Ethyl43$25,368
EliquisApixaban24$22,746
LinzessLinaclotide17$19,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,641$266,401165 claims
AstraZenecaFarxiga, Breztri Aerosphere, Airsupra$1,149$164,982186 claims
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Tradjenta$468$143,058128 claims
Lilly USA, LLCTrulicity, Mounjaro$1,012$85,63074 claims
MerckJanuvia, Janumet$120$82,94073 claims
PfizerEliquis$14$22,74624 claims
AbbVieLinzess$101$19,62217 claims
Astellas Pharma US IncMyrbetriq$530$17,62627 claims
NovartisEntresto$233$17,21012 claims
Johnson & JohnsonXarelto$53$16,00518 claims
Scilex Pharmaceuticals Inc.Elyxyb$774$9,02411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →